The inhibitory effect of aspirin on fibrinolysis is reversed by iloprost, a prostacyclin analogue

V. Bertele, L. Mussoni, G. Pintucci, G. Del Rosso, G. Romano, G. De Gaetano, A. Libretti

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The reduced fibrinolytic response after aspirin intake may be due to prevention of prostacyclin production. The effect of iloprost (a stable prostacyclin analogue) was tested on the fibrinolytic activity (euglobulin lysis area on fibrin plate [E.L.A.], t-PA antigen, PAI activity and PAI-1 antigen) of plasma drawn after venous stasis test from six healthy male volunteers, who each received all the following treatments according to single-blind randomized cross-over design: placebo, iloprost, aspirin + placebo, aspirin + iloprost. The mean E.L.A. value after venous occlusion was significantly higher than the basal level after every treatment but aspirin. Within each treatment group the t-PA antigen levels in response to venous stasis were significantly higher than the basal ones. PAI-1 antigen levels did not change significantly before and after venous stasis either within or among the treatment groups. These data are consistent with the hypothesis that the mechanism related to aspirin's effect on fibrinolysis is mediated by suppression of vessel wall prostacyclin production. Aspirin's inhibitory effect on fibrinolysis was in fact prevented by replacing endogenous prostacyclin with iloprost. Iloprost enhances fibrinolytic activity reduced by aspirin, but not by promoting t-PA release or by inhibiting release of the specific inhibitor, PAI-1.

Original languageEnglish
Pages (from-to)286-288
Number of pages3
JournalThrombosis and Haemostasis
Volume61
Issue number2
Publication statusPublished - 1989

Fingerprint

Iloprost
Fibrinolysis
Epoprostenol
Aspirin
Plasminogen Activator Inhibitor 1
Antigens
Placebos
Serum Globulins
Therapeutics
Fibrin
Cross-Over Studies
Healthy Volunteers

ASJC Scopus subject areas

  • Hematology

Cite this

The inhibitory effect of aspirin on fibrinolysis is reversed by iloprost, a prostacyclin analogue. / Bertele, V.; Mussoni, L.; Pintucci, G.; Del Rosso, G.; Romano, G.; De Gaetano, G.; Libretti, A.

In: Thrombosis and Haemostasis, Vol. 61, No. 2, 1989, p. 286-288.

Research output: Contribution to journalArticle

Bertele, V, Mussoni, L, Pintucci, G, Del Rosso, G, Romano, G, De Gaetano, G & Libretti, A 1989, 'The inhibitory effect of aspirin on fibrinolysis is reversed by iloprost, a prostacyclin analogue', Thrombosis and Haemostasis, vol. 61, no. 2, pp. 286-288.
Bertele, V. ; Mussoni, L. ; Pintucci, G. ; Del Rosso, G. ; Romano, G. ; De Gaetano, G. ; Libretti, A. / The inhibitory effect of aspirin on fibrinolysis is reversed by iloprost, a prostacyclin analogue. In: Thrombosis and Haemostasis. 1989 ; Vol. 61, No. 2. pp. 286-288.
@article{e550b9aa57054ab99346f01dfe92800b,
title = "The inhibitory effect of aspirin on fibrinolysis is reversed by iloprost, a prostacyclin analogue",
abstract = "The reduced fibrinolytic response after aspirin intake may be due to prevention of prostacyclin production. The effect of iloprost (a stable prostacyclin analogue) was tested on the fibrinolytic activity (euglobulin lysis area on fibrin plate [E.L.A.], t-PA antigen, PAI activity and PAI-1 antigen) of plasma drawn after venous stasis test from six healthy male volunteers, who each received all the following treatments according to single-blind randomized cross-over design: placebo, iloprost, aspirin + placebo, aspirin + iloprost. The mean E.L.A. value after venous occlusion was significantly higher than the basal level after every treatment but aspirin. Within each treatment group the t-PA antigen levels in response to venous stasis were significantly higher than the basal ones. PAI-1 antigen levels did not change significantly before and after venous stasis either within or among the treatment groups. These data are consistent with the hypothesis that the mechanism related to aspirin's effect on fibrinolysis is mediated by suppression of vessel wall prostacyclin production. Aspirin's inhibitory effect on fibrinolysis was in fact prevented by replacing endogenous prostacyclin with iloprost. Iloprost enhances fibrinolytic activity reduced by aspirin, but not by promoting t-PA release or by inhibiting release of the specific inhibitor, PAI-1.",
author = "V. Bertele and L. Mussoni and G. Pintucci and {Del Rosso}, G. and G. Romano and {De Gaetano}, G. and A. Libretti",
year = "1989",
language = "English",
volume = "61",
pages = "286--288",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "2",

}

TY - JOUR

T1 - The inhibitory effect of aspirin on fibrinolysis is reversed by iloprost, a prostacyclin analogue

AU - Bertele, V.

AU - Mussoni, L.

AU - Pintucci, G.

AU - Del Rosso, G.

AU - Romano, G.

AU - De Gaetano, G.

AU - Libretti, A.

PY - 1989

Y1 - 1989

N2 - The reduced fibrinolytic response after aspirin intake may be due to prevention of prostacyclin production. The effect of iloprost (a stable prostacyclin analogue) was tested on the fibrinolytic activity (euglobulin lysis area on fibrin plate [E.L.A.], t-PA antigen, PAI activity and PAI-1 antigen) of plasma drawn after venous stasis test from six healthy male volunteers, who each received all the following treatments according to single-blind randomized cross-over design: placebo, iloprost, aspirin + placebo, aspirin + iloprost. The mean E.L.A. value after venous occlusion was significantly higher than the basal level after every treatment but aspirin. Within each treatment group the t-PA antigen levels in response to venous stasis were significantly higher than the basal ones. PAI-1 antigen levels did not change significantly before and after venous stasis either within or among the treatment groups. These data are consistent with the hypothesis that the mechanism related to aspirin's effect on fibrinolysis is mediated by suppression of vessel wall prostacyclin production. Aspirin's inhibitory effect on fibrinolysis was in fact prevented by replacing endogenous prostacyclin with iloprost. Iloprost enhances fibrinolytic activity reduced by aspirin, but not by promoting t-PA release or by inhibiting release of the specific inhibitor, PAI-1.

AB - The reduced fibrinolytic response after aspirin intake may be due to prevention of prostacyclin production. The effect of iloprost (a stable prostacyclin analogue) was tested on the fibrinolytic activity (euglobulin lysis area on fibrin plate [E.L.A.], t-PA antigen, PAI activity and PAI-1 antigen) of plasma drawn after venous stasis test from six healthy male volunteers, who each received all the following treatments according to single-blind randomized cross-over design: placebo, iloprost, aspirin + placebo, aspirin + iloprost. The mean E.L.A. value after venous occlusion was significantly higher than the basal level after every treatment but aspirin. Within each treatment group the t-PA antigen levels in response to venous stasis were significantly higher than the basal ones. PAI-1 antigen levels did not change significantly before and after venous stasis either within or among the treatment groups. These data are consistent with the hypothesis that the mechanism related to aspirin's effect on fibrinolysis is mediated by suppression of vessel wall prostacyclin production. Aspirin's inhibitory effect on fibrinolysis was in fact prevented by replacing endogenous prostacyclin with iloprost. Iloprost enhances fibrinolytic activity reduced by aspirin, but not by promoting t-PA release or by inhibiting release of the specific inhibitor, PAI-1.

UR - http://www.scopus.com/inward/record.url?scp=0024593873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024593873&partnerID=8YFLogxK

M3 - Article

C2 - 2473539

AN - SCOPUS:0024593873

VL - 61

SP - 286

EP - 288

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 2

ER -